文献速递冠心病血脂与心血管预防

FOURIER 试验中生物标志物对复杂冠状动脉血运重建的预测

Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

FOURIER 试验纳入 27,564 例稳定动脉粥样硬化患者,分析基线生物标志物与主要冠脉事件及复杂血运重建的关联。多标志物评分越高,主要冠脉事件与复杂血运重建风险呈显著阶梯式升高,且与左主干、多支病变或慢性完全闭塞相关。

要点

  • 多标志物评分升高与主要冠脉事件风险呈阶梯式关联。
  • 评分升高亦与复杂血运重建及其组分风险增加相关。
  • 评分与血运重建时左主干、多支病变或慢性完全闭塞相关。

核心结论

  • 基于生物标志物的策略可识别有冠脉事件风险的稳定患者,包括冠脉旁路移植术和复杂经皮冠状动脉介入治疗。
  • 该策略还可预测血运重建时的高危冠脉解剖。

研究设计与样本

  • FOURIER 为随机试验,比较 PCSK9 抑制剂 evolocumab 与安慰剂,纳入 27,564 例稳定动脉粥样硬化患者。
  • 分析基线生物标志物与主要冠脉事件及复杂血运重建的校正关联,采用多标志物评分。

主要发现

  • 按升高生物标志物数量分组:0 个 n=6,444;1-2 个 n=12,439;≥3 个 n=2,761。
  • 主要冠脉事件风险:中间评分 HRadj 1.57(95%CI 1.38-1.78),高评分 HRadj 2.90(95%CI 2.47-3.40)。
  • 复杂血运重建风险:中间评分 HRadj 1.33(95%CI 1.06-1.67),高评分 HRadj 2.07(95%CI 1.52-2.83)。
  • 复杂血运重建各组分趋势检验 Ptrend<0.05。
  • 升高生物标志物数量与血运重建时左主干病变、多支病变或慢性完全闭塞相关(每项 P<0.05)。

关键数值与推荐

  • 多标志物评分每项升高生物标志物计 1 分:高敏 C 反应蛋白≥2 mg/L。
  • N 末端 B 型利钠肽原≥450 pg/mL。
  • 高敏肌钙蛋白 I≥6 ng/L。
  • 生长分化因子-15≥1,800 pg/mL。

临床怎么用

  • 对稳定动脉粥样硬化患者可检测上述生物标志物构建评分,辅助识别主要冠脉事件及复杂血运重建高风险者。
  • 评分升高提示血运重建时可能存在左主干、多支病变或慢性完全闭塞,可供术前规划参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biomarkers are known to predict major adverse cardiovascular events. However, the association of biomarkers with complex coronary revascularization procedures or high-risk coronary anatomy at the time of revascularization is not understood. OBJECTIVES: We examined the associations between baseline biomarkers and major coronary events (MCE) and complex revascularization procedures. METHODS: FOURIER was a randomized trial of the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab vs placebo in 27,564 patients with stable atherosclerosis. We analyzed adjusted associations among the biomarkers, MCE (coronary death, myocardial infarction, or revascularization), and complex revascularization (coronary artery bypass graft or complex percutaneous coronary intervention) using a multimarker score with 1 point assigned for each elevated biomarker (high-sensitivity C-reactive protein ≥2 mg/L; N-terminal pro-B-type natriuretic peptide ≥450 pg/mL; high-sensitivity troponin I ≥6 ng/L; growth-differentiation factor-15 ≥1,800 pg/mL). RESULTS: When patients were grouped by the number of elevated biomarkers (0 biomarkers, n = 6,444; 1-2 biomarkers, n = 12,439; ≥3 biomarkers, n = 2,761), there was a significant graded association between biomarker score and the risk of MCE (intermediate score: HRadj: 1.57 [95% CI: 1.38-1.78]; high score: HRadj: 2.90 [95% CI: 2.47-3.40]), and for complex revascularization (intermediate: HRadj: 1.33 [95% CI: 1.06-1.67]; high score: HRadj: 2.07 [95% CI: 1.52-2.83]) and its components (Ptrend <0.05 for each). The number of elevated biomarkers also correlated with the presence of left main disease, multivessel disease, or chronic total occlusion at the time of revascularization (P < 0.05 for each). CONCLUSIONS: A biomarker-based strategy identifies stable patients at risk for coronary events, including coronary artery bypass graft surgery and complex percutaneous coronary intervention, and predicts high-risk coronary anatomy at the time of revascularization. These findings provide insight into the relationships between cardiovascular biomarkers, coronary anatomical complexity, and incident clinical events. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Fagundes A, Morrow DA, Oyama K, et al. Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. J Am Coll Cardiol. 2022. PMID: 36007987. doi:10.1016/j.jacc.2022.05.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。